Clinical Report: Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies

Overview

A pilot program at Fox Chase Cancer Center demonstrated that outpatient monitoring for T-cell redirecting therapies significantly reduced hospital stays without compromising patient safety. This approach not only optimized healthcare resources but also minimized patient disruption and costs.

Background

T-cell redirecting therapies, such as CAR T and BiTEs, represent a significant advancement in the treatment of blood cancers like lymphoma and multiple myeloma. Traditionally, patients receiving these therapies have required prolonged hospitalization to monitor for side effects. The shift towards outpatient monitoring is crucial as it can enhance patient quality of life while addressing healthcare resource constraints.

Data Highlights

The study showed that outpatient observation led to:

• Significant reduction in hospital admissions for CAR T and BiTE patients.
• More than half of BiTE patients avoided hospitalization entirely.
• No adverse safety events reported during the outpatient monitoring.
• Patients experienced decreased disruption to their normal lives.

Key Findings

• Outpatient T-cell redirecting therapy was successfully implemented for patients with relapsed lymphoma and multiple myeloma.
• Patients in the outpatient CAR T program experienced a reduction in total hospital stay.
• Structured outpatient monitoring included daily toxicity assessments and caregiver support.
• Close communication and education about warning signs were critical for patient safety.
• The program's design allows for easy reproduction in other healthcare settings.

Clinical Implications

Healthcare providers should consider implementing outpatient monitoring models for patients receiving T-cell redirecting therapies to enhance patient care and reduce hospital resource utilization. Proper caregiver support and education are essential components of this model to ensure patient safety.

Conclusion

The successful implementation of outpatient monitoring for T-cell redirecting therapies at Fox Chase Cancer Center suggests a promising shift in treatment paradigms that could improve patient outcomes and optimize healthcare resources.

References

1. Fox Chase Cancer Center, ASH Annual Meeting, 2023 -- Delivering CAR-T and BiTEs Outpatient: A Safe and Resource-Conscious Model for T-Cell Redirecting Therapies
2. ophthalmology management — The Promise of Home Monitoring
3. The ASCO — Remote Monitoring Program Reduced Hospitalization Among Patients With Cancer Infected With COVID-19
4. The ASCO Post — Text Message–Based Prescreening Could Benefit Patients Receiving Immunotherapy
5. Ophthalmology Management — The Promise of Home Monitoring
6. The Promise of Home Monitoring
7. Remote Monitoring Program Reduced Hospitalization Among Patients With Cancer Infected With COVID-19
8. Text Message–Based Prescreening Could Benefit Patients Receiving Immunotherapy
9. ASTCT Practice Guidelines for Outpatient CAR-T Therapy
10. EPKINLY as Monotherapy for FL